AD 2603
Alternative Names: AD-2603Latest Information Update: 31 Jul 2024
At a glance
- Originator BioArctic
- Class Antibodies; Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Alzheimer's disease
Most Recent Events
- 31 Jul 2024 AD 2603 is still in research for Alzheimer's disease in Sweden (Bioarctic Pipeline, July 2024)
- 28 Jan 2024 No recent reports of development identified for research development in Alzheimer's-disease in Sweden
- 27 Mar 2020 AD 2603 is available for licensing as of 27 Mar 2020. https://www.bioarctic.se/